Characteristic		Endpoint reported in publication	Endpoint not reported in publication	Time of measurementa
Ludvik 2002	Review's primary outcomes
	Gycaemic control	x		0, 1.5 months
	Morbidity		x
	Adverse effects	x		0, 1.5 months
	Review's secondary outcomes
	Serum insulin, C‐peptide or insulin sensitivity		x
	Body weight or BMI	x		0, 1.5 months
	Lipids (total, LDL‐ and HDL‐cholesterol; triglycerides)	x		0, 1.5 months
	Health‐related quality of life		x
	Well‐being		x
	Physical and cognitive function		x
	Costs		x
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Blood pressure (S): 0, 1.5 mo
	Subgroups reported in publication
	‐
Ludvik 2004	Review's primary outcomes
	Gycaemic control	x		0, 2, 3 mo
	Morbidity		x
	Adverse effects	x		0, 2, 3 mo
	Review's secondary outcomes
	Serum insulin, C‐peptide or insulin sensitivity		x
	Body weight or BMI	x		0, 2, 3 mo
	Lipids (total, LDL‐ and HDL‐cholesterol; triglycerides)	x		0, 2, 3 mo
	Health‐related quality of life		x
	Well‐being		x
	Physical and cognitive function		x
	Costs		x
	Outcomes other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Blood pressure: 0, 2, 3 months
	Subgroups reported in publication
	‐
Ludvik 2008	Review's primary outcomes
	Gycaemic control	x		0, 5 months
	Morbidity		x
	Adverse effects	x		0, 5 months
	Review's secondary outcomes
	Serum insulin, C‐peptide or insulin sensitivity	x		0, 5 months
	Body weight or BMI		x
	Lipids (total, LDL‐ and HDL‐cholesterol; triglycerides)	x		0, 5 months
	Health‐related quality of life		x
	Well‐being		x
	Physical and cognitive function		x
	Costs		x
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Adiponectin, fibrinogen: 0, 5 months
	Subgroups reported in publication
Footnotes aUnderlined data denote times of measurement for primary and secondary review outcomes, if measured and reported in the results section of the publication (other times represent planned but not reported points in time) b(P) Primary or (S) secondary endpoint(s) refer to verbatim statements in the publication, (O) other endpoints relate to outcomes which were not specified as 'primary' or 'secondary' outcomes in the publication BMI: body mass index; HDL: high‐density lipoprotein; LDL: low‐density lipoprotein; N/A: not applicable